About this Research Topic
According to the NCI Dictionary of Cancer Terms, Liquid Biopsy is “a test done on a sample of blood to look for cancer cells from a tumor that are circulating in the blood (CTCs) or for pieces of DNA from tumor cells that are in the blood (ctDNA)". However, this definition does not take account of the plethora of tumor cell products, eg, cell-free circulating nucleic acids, ctDNA, cfRNA, extracellular vesicles or proteins, that may act as biomarkers.
Liquid biopsy is an area of active research and many advances have been made in the development of technologies detecting blood-based, tumor-specific biomarkers useful to improve molecular characterization, guiding treatment decision and optimizing follow up strategies.
This Research Topic will focus on the current and future clinical applications of liquid biopsy in terms of:
Current and future clinical application of liquid biopsy in terms of:
1. Detection of early and advanced disease
2. Monitoring of the disease (early and advanced disease, treatment response)
3. Molecular assessment (techniques, validated biomarkers, emerging biomarkers, epigenetics)
4. Development of new treatment strategies based on liquid biopsy
--
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Liquid biopsy is an area of active research and many advances have been made in the development of technologies detecting blood-based, tumor-specific biomarkers useful to improve molecular characterization, guiding treatment decision and optimizing follow up strategies.
This Research Topic will focus on the current and future clinical applications of liquid biopsy in terms of:
Current and future clinical application of liquid biopsy in terms of:
1. Detection of early and advanced disease
2. Monitoring of the disease (early and advanced disease, treatment response)
3. Molecular assessment (techniques, validated biomarkers, emerging biomarkers, epigenetics)
4. Development of new treatment strategies based on liquid biopsy
--
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Liquid Biopsy, Metastasis, Colorectal Cancer, Minimal Residual Disease, Tumor Heterogeneity, BRAF, RAS, HER2
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
